Mumbai serves as the corporate headquarters of the international Indian pharmaceutical business Cipla Limited, often known as Cipla. Cipla mainly creates drugs to address disorders like depression, rheumatoid arthritis, diabetes, and cardiovascular disease. Cipla offers its goods in 86 countries and operates 47 manufacturing facilities worldwide. It is India’s third-biggest pharmaceutical manufacturer.
Cipla Company Details
| Company Name | Cipla Limited |
| Origin Country | India |
| Founded | 1935 |
| Chairman | Dr. Y. K. Hamied |
| Managing Director & CEO | Umang Vohra |
| Headquarters | Mumbai, Maharashtra, India |
| Products/Services | Pharmaceuticals, Biotechnology, API Manufacturing, Healthcare Solutions |
| Number of Employees | Over 25,000 (as of 2022) |
| Official Website | www.cipla.com |
History
Khwaja Abdul Hamied established Cipla as Mumbai’s Chemical, Industrial & Pharmaceutical Laboratories in 1935. The company’s name was changed to “Cipla” in July 1984. Cipla was established with the exclusive goal of ensuring that everyone has access to healthcare. He established the pharmaceutical company as the first Indian founder.
Care is the cornerstone upon which Cipla, as an organization, has been constructed, brick by brick. They have increased our global reach to more than 80 countries, offering more than 1,500 products in more than 50 dosage forms and a variety of therapeutic categories. They are expanding their footprint in important countries, including India, South Africa, and the United States, as well as other developing nations, to lower the cost of healthcare on a worldwide scale.
Products and services
Cipla distributes pharmaceutical and personal care goods, such as the antidepressants lamivudine, escitalopram oxalate, fluticasone propionate, and active medicinal ingredients, to other producers. Cipla is the biggest producer of antiretroviral medications worldwide.
Cipla produces metered-dose spacers, inhaler devices, and related equipment. It also engages in research and development to create novel medications and drug delivery methods.
In July 2020, the business announced the release of Gilead Sciences’ Remdesivir under the brand name CIPREMI in India after striking a voluntary licensing agreement with the parent company obtaining DCGI permission for “restricted emergency use” in COVID-19 treatment of patients with a critical condition.
Operations
The business operates in several countries, including South Africa, Canada, the US, India, and significantly regulated and emerging markets. The head office of Cipla is located in Mumbai, Maharashtra, India.
Anantha Nageswaran is the chief editor and writer at TheBusinessBlaze.com. He specialises in business, finance, insurance, loan investment topics. With a strong background in business-finance and a passion for demystifying complex concepts, Anantha brings a unique perspective to his writing.
